Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Quinsair | Levofloxacin | Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections | Reimburse with clinical criteria and/or conditions | Complete | ||
Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Ilaris | Canakinumab | Systemic Juvenile Idiopathic Arthritis | Reimburse with clinical criteria and/or conditions | Complete | ||
XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Caprelsa | Vandetanib | Medullary Thyroid Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Reimburse with clinical criteria and/or conditions | Complete |